Experts in Personalized Medicine to Meet at 4th Annual Personalized Medicine Conference in Boston

May 31, 2012 - PRLog -- Personalized medicine has the potential to revolutionize medical care by utilizing an improved understanding of genetics and molecular biology to allow for better, more precise diagnostic tests, greater predictability of disease course, and improved patient safety by selecting not only the right drug for a patient, but also the proper dosage to reduce adverse effects.
      
Robert C. Green, MD, MPH will discuss the impact that whole genome sequencing will have on the practice of medicine, patients, and health care costs, as well as the potential risks associated with its use. His work with the G2P Research Program, Partners Center for Personalized Genetic Medicine, Brigham and Women’s Hospital, and Harvard Medical School provide an extensive background for his presentation, Empirical Studies in the Implementation of Genomic Medicine.

Dora Dias-Santagata, Ph.D., who is an instructor of Pathology at Harvard Medical School and the Co-Director of the Translational Research Laboratory at Mass General, will be describing her experience in developing and implementing a clinical platform for broad-base tumor genotyping. She will also outline the challenges that arose in her clinical testing. Her presentation, Clinical Implementation of Large-Scale Tumor Genotyping to Guide Personalized Cancer Care, will also include some interesting patient cases with clinical follow-up.

Also presenting at the conference will be Bryan Loy, MD of Humana. He will describe the various perspectives that must be considered when addressing the payment methods for molecular diagnostics. He will discuss the issue of more widely integrating personalized medicine, while keeping the health plan, the consumer, and the provider in mind.

Please visit www.personalized-medicine-conference.com for the full list of speakers, a preliminary agenda, and information on how to register to attend.